Dew Have U looked at PRTO ?
My wife works with dialysis patients , she did CKD research at Yale.
Her Renal Dept has been recruiting for PRTO's PATENCY 1 and PATENCY 2 trials .
These trials are double blinded, folks ...no insider info here .
Anyway Dew I'll give you what I have and would appreciate your comments .
Novartis originally had an option on their program ( to improve / maintain patency ( blood flow ) in fistulas , essential for dialysis )
They declined to exercise their option $550m ...or at least they couldn't come to terms .
PRTO IPO'd at $10 a share in 2014 and went ahead on their own ...almost sound like the ZSPH story ( hyperkalemia )
Phase 3 PATENCY 1 was enrolled ahead of schedule and should read out in Dec 2016
Phase 3 PATENCY 2 seemed to have a slowed / delayed enrollment ...may be related to slight change/emphasis in end points ...see clinicaltrials.gov history of changes but is up and running now.
PRTO has funds thru 2017 ...enough to finish PATENCY 1 , but not enough to finish PATENCY 2 . Believe their program is Fast Tracked and also Orphan Drug designated..
PRTO presented at a recent conference ...Webcast is available thru their web site
They also filed a CT order ... SEC confidential treatment order..so I'm wondering if they are back in talks with Novartis ...who you may know has a presence in Renal.
Believe its now Abingworth LLP's 2nd largest position .
Baker Bros and Alta Partners also have positions .
So about Fistula's ( AVF ) and dialysis .
Fistula blockage is a major problem for dialysis patients . My wife deals with it every week. Some of her patients have fistula tracks completely up both arms ...as one fails they start a new one higher up.
Hospitals spend around $17,000 per dialysis patient maintaining or reworking fistula's...PRTO's figures.
So there is a real demand for anything that will reduce Fistula failure.
PRTO thinks they can reduce Fistual failure by 20-30 % with their Vonapantise drug ( applied during creation of the Fistula )
Would appreciate your comments
PRTO has spiked recently ( post conference and CT order )
Thx
Kiwi
PS for anyone else reading this . If their P 3 trial fails , this stock is going to a $1. Risk only what you can afford to lose.
